This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up
by Zacks Equity Research
Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Are Options Traders Betting on a Big Move in Merit Medical (MMSI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Merit Medical (MMSI) stock based on the movements in the options market lately.
Implied Volatility Surging for Merit Medical (MMSI) Stock Options
by Zacks Equity Research
Merit Medical (MMSI) needs investors to pay close attention to the stock based on moves in the options market lately.
Medical - Dental Supplies Outlook: Long-Term Prospects Bright
by Zacks Equity Research
The ongoing digital transition is posing challenges to dental industry players in the wake of growing oral hygiene awareness and increasing incidence of dental diseases.
Why Is Merit Medical (MMSI) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
COO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COO vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
by Zacks Equity Research
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Merit Medical's (MMSI) acquisition-driven strategy to boost growth by expanding existing product offerings across all business segments in Q2.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed
by Zacks Equity Research
Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed
7 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Here's Why You Should Hold Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Here we take a quick look at the major factors that plague Merit Medical (MMSI) and discuss the prospects that ensure near-term recovery.
Merit Medical (MMSI) Up 18.9% in a Month on Solid Q1 Earnings
by Zacks Equity Research
Merit Medical (MMSI) reports strong Q1 earnings and sees solid growth across segments and geographies.
Zacks.com highlights: VMware, PetMed Express, Merit Medical Systems, Dollar General and inTEST
by Zacks Equity Research
Zacks.com highlights: VMware, PetMed Express, Merit Medical Systems, Dollar General and inTEST
Can High Revenues Aid SBA Communications (SBAC) Q1 Earnings?
by Zacks Equity Research
While higher consolidated revenues might benefit SBA Communications (SBAC) in Q1 earnings, its financials are likely to be affected by high customer concentration & consolidation in wireless industry.
Nokia (NOK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues are likely to aid Nokia (NOK) to surpass earnings estimates in the to-be-reported quarter.
What to Expect From International Paper (IP) in Q1 Earnings?
by Zacks Equity Research
Despite contraction in gross estimated revenues figure, can International Paper (IP) beat market estimates in this quarter? Here are some clues for investors.
What Makes Patterson Companies (PDCO) a Strong Sell?
by Zacks Equity Research
Patterson Companies (PDCO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Becton, Dickinson (BDX), Bard Receive Regulatory Nod in China
by Zacks Equity Research
Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.
Is a Beat in Store for Walgreens Boots (WBA) in Q1 Earnings?
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division continues to witness comparable prescription growth as well as a robust retail prescription market.
Becton, Dickinson (BDX) a Step Closer to Bard Acquisition
by Zacks Equity Research
Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.
Merit Medical Deserves a Place in Your Portfolio: Here's Why
by Zacks Equity Research
A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.